跳至主要内容
临床试验/NCT04482985
NCT04482985Unknown4 期

Meclizine Plasma Levels in Responders and Non-responders

Medical Corps, Israel Defense Force0 个研究点目标入组 50 人开始时间: 2020年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
50
主要终点
Meclizine plasma levels

研究概览

简要总结

Motion sickness is a debilitating condition that can effect many crew members. Meclizine has long been known as an effective anti motion sickness drug. The response to the drug is variable - some are responders, while others are resistant to the drug. The aim of the present study is to examine whether there is a correlation between meclizine plasma levels and clinical response.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Seasickness questioner (WIKER) score of
  • Subjective functioning at 1 meter sea voyage - 5/10 and lower.
  • Subjects who were prescribed 25mg of meclizine.
  • Subjects who did not take any other drugs 48 prior to their participation in the study.

排除标准

  • Known hearing loss or any vestibular impairment
  • Vertigo complains
  • Any ear infection
  • Use of Scopolamine based anti-seasickness drugs.
  • Use of meclizine 50mg.

研究组 & 干预措施

Meclizine responders

Active Comparator

干预措施: Meclizine Hydrochloride (Drug)

Meclizine non responders

Active Comparator

干预措施: Meclizine Hydrochloride (Drug)

结局指标

主要结局

Meclizine plasma levels

时间窗: 2 hours after meclizine administration

ng/dl

次要结局

未报告次要终点

研究者

发起方
Medical Corps, Israel Defense Force
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yoni Gutkovich

deputy of the head of department for the human performance laboratory, the Israeli naval institute, Haifa.

Medical Corps, Israel Defense Force

相似试验